2-氯-3-环丙基-3-氧代丙酸乙酯 | 1033707-26-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-氯-3-环丙基-3-氧代丙酸乙酯
• 英文名称: ethyl 2-chloro-3-cyclopropyl-3-oxopropanoate
• CAS: 1033707-26-4
• 化学式: C₈H₁₁ClO₃
• 分子量: 190.627
• InChiKey: QSHKICZTKZLOHX-UHFFFAOYSA-N

物化性质

• 沸点：
  242.0±20.0 °C(Predicted)
• 密度：
  1.277±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氯-3-环丙基-3-氧代丙酸乙酯 在 盐酸 、 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 为溶剂， 反应 5.5h， 生成 ethyl 4-cyclopropyl-2-(2-methoxyethoxy)thiazole-5-carboxylate
  参考文献：
  名称：

  Optimization of Brain Penetrant 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors and in Vivo Testing in Diet-Induced Obese Mice

  摘要：

  11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) has been widely considered by the pharmaceutical industry as a target to treat metabolic syndrome in type II diabetics. We hypothesized that central nervous system (CNS) penetration might be required to see efficacy. Starting from a previously reported pyrimidine compound, we removed hydrogen-bond donors to yield 3, which had modest CNS penetration. More significant progress was achieved by changing the core to give 40, which combines good potency and CNS penetration. Compound 40 was dosed to diet-induced obese (DIO) mice and gave excellent target engagement in the liver and high free exposures of drug, both peripherally and in the CNS. However, no body weight reduction or effects on glucose or insulin were observed in this model. Similar data were obtained with a structurally diverse thiazole compound 51. This work casts doubt on the hypothesis that localized tissue modulation of 11 beta-HSD1 activity alleviates metabolic syndrome.

  DOI：

  10.1021/jm4016729
• 作为产物：
  描述：

  3-环丙基-3-羰基-丙酸乙酯 在 磺酰氯 作用下， 以 二氯甲烷 为溶剂， 生成 2-氯-3-环丙基-3-氧代丙酸乙酯
  参考文献：
  名称：

  新一代 sGC 刺激剂：咪唑并[1,2-a]吡啶甲酰胺 BAY 1165747 (BAY-747) 的发现，一种用于治疗顽固性高血压的长效可溶性鸟苷酸环化酶刺激剂

  摘要：

  在此，我们描述了新型可溶性鸟苷酸环化酶（sGC）刺激剂的鉴定、化学优化和临床前表征。鉴于 sGC 刺激剂具有非常广泛的治疗机会，未来将需要针对具有特定药代动力学、组织分布和理化特性的不同适应症的新定制分子。在这里，我们报告了基于超高通量 (uHTS) 从咪唑并[1,2- a ]吡啶先导系列中发现的一类新型 sGC 刺激剂。通过对初始筛选目标进行广泛和交错的优化，效力、代谢稳定性、渗透性和溶解度等特性可以同时得到显着改善。这些努力最终导致了新的 sGC 刺激器的发现22和28。事实证明，BAY 1165747 (BAY-747, 28 ) 可能是高血压患者的理想治疗替代方案，尤其是那些对标准抗高血压治疗（难治性高血压）没有反应的患者。BAY-747 ( 28 ) 在 1 期研究中证明了长达 24 小时的持续血流动力学效应。

  DOI：

  10.1021/acs.jmedchem.2c02082

文献信息

• Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20140128372A1

  公开（公告）日：2014-05-08

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代咪唑[1,2-a]吡啶-3-羧酰胺，其制备方法，单独或组合使用以治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20140128386A1

  公开（公告）日：2014-05-08

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代咪唑[1,2-a]吡啶-3-羧酰胺，以及它们的制备方法，单独或组合使用于治疗和/或预防疾病，以及用于制备用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• Design of Potent and Druglike Nonphenolic Inhibitors for Catechol <i>O</i>-Methyltransferase Derived from a Fragment Screening Approach Targeting the <i>S</i>-Adenosyl-<scp>l</scp>-methionine Pocket
  作者：Christian Lerner、Roland Jakob-Roetne、Bernd Buettelmann、Andreas Ehler、Markus Rudolph、Rosa María Rodríguez Sarmiento

  DOI：10.1021/acs.jmedchem.6b00927

  日期：2016.11.23

  A fragment screening approach designed to target specifically the S-adenosyl-l-methionine pocket of catechol O-methyl transferase allowed the identification of structurally related fragments of high ligand efficiency and with activity on the described orthogonal assays. By use of a reliable enzymatic assay together with X-ray crystallography as guidance, a series of fragment modifications revealed an

  专门针对儿茶酚O的S-腺苷-1-蛋氨酸口袋设计的片段筛选方法-甲基转移酶可以鉴定具有高配体效率的结构相关片段，并且对所述正交试验具有活性。通过将可靠的酶促测定与X射线晶体学一起用作指导，一系列片段修饰揭示了SAR，经过几次扩展后，可以获得有效的先导化合物。首次报道了非酚类和小的低纳摩尔浓度的强效SAM竞争性COMT抑制剂。这些化合物代表了一系列新的有效COMT抑制剂，这些抑制剂可能会进一步优化用于治疗帕金森氏病，左旋多巴治疗或精神分裂症的辅助药物。
• Discovery of novel dihydroimidazothiazole derivatives as p53–MDM2 protein–protein interaction inhibitors: Synthesis, biological evaluation and structure–activity relationships
  作者：Masaki Miyazaki、Haruko Kawato、Hiroyuki Naito、Masahiro Ikeda、Masaya Miyazaki、Mayumi Kitagawa、Takahiko Seki、Setsuko Fukutake、Masashi Aonuma、Tsunehiko Soga

  DOI：10.1016/j.bmcl.2012.08.086

  日期：2012.10

  Starting with Nutlins as an initial lead, we designed and generated bicyclic scaffolds aiming to place cis-bischlorophenyl moiety at the equivalent location where the hydrophobic interaction with MDM2 could be expected. As a result, we discovered novel MDM2 inhibitors possessing a dihydroimidazothiazole scaffold. Further exploration of the side chains on the dihydroimidazothiazole scaffold aided by

  我们从Nutlins作为最初的线索开始，设计并生成了双环支架，旨在将顺式-双氯苯基部分置于与MDM2可能发生疏水相互作用的等效位置。结果，我们发现了具有二氢咪唑并噻唑支架的新型MDM2抑制剂。在分子模型的辅助下，对二氢咪唑并噻唑支架上侧链的进一步研究导致化合物显示出与Nutlin-3a几乎相同的体外效价。
• Structure-based design and synthesis of novel furan-diketopiperazine-type derivatives as potent microtubule inhibitors for treating cancer
  作者：Zhongpeng Ding、Feifei Li、Changjiang Zhong、Feng Li、Yuqian Liu、Shixiao Wang、Jianchun Zhao、Wenbao Li

  DOI：10.1016/j.bmc.2020.115435

  日期：2020.5

  tert-butyl moiety at the 5-position of imidazole was essential for the activity of such compounds. Immunofluorescence assay indicated that compounds 17o and 17p could efficiently inhibit microtubule polymerization. Overall, the novel furan-diketopiperazine-type derivatives could be considered as a potential scaffold for the development of anti-cancer drugs.

  海洋生物天然产物“ diketopiperazine phenylahistin”的合成类似物Plinabulin对微管具有解聚作用，并靶向秋水仙碱位点，秋水仙碱位点已进入III期临床试验，用于治疗非小细胞肺癌（NSCLC）和非小细胞肺癌。预防化疗引起的中性粒细胞减少症（CIN）。为了开发更有效的抗微管和细胞毒性衍生物，总结并分析了纤连蛋白衍生物的共晶体复合物。我们对咪唑型衍生物的叔丁基部分或C环进行了进一步修饰，以通过引入不同骨架的新型骨架建立分子库。我们的结构活性关系研究表明，化合物17o（IC50 = 14.0 nM，NCI-H460）和17p（IC50 = 2.9 nM，具有呋喃基团的NCI-H460）在纳摩尔水平上针对各种人类癌细胞系表现出强力的细胞毒活性。特别是呋喃基团的5-甲基或甲氧基甲基取代基可以取代咪唑在5位上的烷基以维持细胞毒活性，这与以前的报道相反，咪唑5位上的叔丁基